Filing Flows › Coya Therapeutics (COYA) › Q2 2026
Coya Therapeutics (COYA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Coya Therapeutics (COYA) reported revenue of $244K for the second quarter 2026 (Q2 2026), +49% from a year earlier and -3% from the quarter before.
Coya Therapeutics, Q2 2026: revenue $244K (+49% year over year), net loss $6.6M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $244K | -3% | +49% |
| Operating profit | −$7.0M | — | — |
| Net earnings | −$6.6M | — | — |
| Operating cash flow | −$7.4M | — | — |
What changed
Revenue was $244K in Q2 2026, up 49% year over year and down 3% from the previous quarter.
Operating costs exceeded revenue by $7.0M, an operating margin of -2891.1%. Total costs grew 11% against revenue growth of 49%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $6.6M, narrower than the previous quarter's $7.2M loss.
Operating cash flow was −$7.4M. Non-cash charges added back $3K of depreciation and $944K of share-based compensation. Working capital and other items used $1.7M.
Questions
What was Coya Therapeutics' revenue in the second quarter 2026?
Coya Therapeutics (COYA) reported revenue of $244K for the second quarter 2026 (Q2 2026), +49% from a year earlier and -3% from the quarter before.
Source: Coya Therapeutics 10-Q on SEC EDGAR.